Critical Contrast: Annovis Bio (NYSE:ANVS) vs. Sana Biotechnology (NASDAQ:SANA)

Annovis Bio (NYSE:ANVS) and Sana Biotechnology (NASDAQ:SANA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.

Institutional and Insider Ownership

15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are owned by institutional investors. 20.8% of Annovis Bio shares are owned by insiders. Comparatively, 30.1% of Sana Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Annovis Bio has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500. Comparatively, Sana Biotechnology has a beta of 1.96, suggesting that its share price is 96% more volatile than the S&P 500.

Profitability

This table compares Annovis Bio and Sana Biotechnology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-153.50%	-125.51%
Sana Biotechnology	N/A	-98.93%	-41.01%

Earnings and Valuation

This table compares Annovis Bio and Sana Biotechnology”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$24.59 million	($1.44)	-1.73
Sana Biotechnology	N/A	N/A	-$244.17 million	($0.97)	-3.25

Sana Biotechnology is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Annovis Bio and Sana Biotechnology, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1	1	2	0	2.25
Sana Biotechnology	1	1	7	0	2.67

Annovis Bio presently has a consensus price target of $13.50, indicating a potential upside of 442.82%. Sana Biotechnology has a consensus price target of $7.83, indicating a potential upside of 148.68%. Given Annovis Bio’s higher probable upside, equities analysts plainly believe Annovis Bio is more favorable than Sana Biotechnology.

Summary

Sana Biotechnology beats Annovis Bio on 8 of the 10 factors compared between the two stocks.

About Annovis Bio

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

About Sana Biotechnology

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company’s product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin’s lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam’s proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.